The Long-Term Cost of GLP-1 Treatment

The long-term cost of GLP-1 treatment in the UK depends far more on how long you stay on it than on the price of any single month. Trials of semaglutide (Wegovy) and tirzepatide (Mounjaro) consistently show that weight is often regained after the medicine is stopped, which is why many specialists now treat obesity as a chronic condition that may need ongoing treatment. For people paying privately, that turns a monthly cost into a potentially open-ended one. This guide explains what the evidence says about stopping and continuing, the factors that drive total cost, and how to plan with your prescriber. We do not quote prices; see our prices page for current comparisons.

Why duration matters most

When people first look at GLP-1 treatment, they often focus on the price of the first month or the cost of a single pen. But two features of these medicines make the long-term view more important:

1. The dose usually increases during the first months. Mounjaro starts at 2.5mg and Wegovy at 0.25mg, with step-ups usually every four weeks. Many providers charge more for higher strengths, particularly since Eli Lilly's September 2025 Mounjaro price rise.
2. The effect generally lasts only while you take the medicine. GLP-1 medicines reduce appetite through their action on gut hormone receptors and the brain. When they are stopped, appetite tends to return to previous levels within weeks.

Together, these mean the cost of a year or more of treatment can be very different from what the first month suggests. Our guide to how weight loss injection pricing works explains how dose and price interact.

What the evidence shows about stopping

Several large trials have looked at what happens when GLP-1 medicines are stopped.

Figures are rounded averages from the published trials.

These results do not mean everyone regains all their weight, nor that treatment is wasted if stopped. Some people maintain a meaningful proportion of their weight loss. But on average, stopping was followed by significant regain, and improvements in measures such as blood pressure and blood sugar also tended to reverse as weight returned.

For more on this, see our guides to weight regain after stopping GLP-1s and long-term GLP-1 use.

Obesity as a chronic condition

The pattern of regain after stopping is one reason many clinicians compare GLP-1 medicines to treatments for other long-term conditions, such as blood pressure or cholesterol medicines, which work only while they are taken. NICE guideline NG246 recognises obesity as a long-term condition needing ongoing support.

This view has important cost implications. If obesity is a chronic disease and the medicine controls rather than cures it, then the cost of treatment is ongoing for as long as you choose to manage it this way. That is a very different financial decision from a fixed-length course of treatment. See our guide to obesity as a chronic disease.

What drives the total cost

1. How long you stay on treatment

This is the single biggest factor. Treatment for six months, two years and five years will have very different total costs, even at the same monthly price.

2. The dose you settle on

Not everyone needs the maximum dose. In SURMOUNT-1, average weight loss over 72 weeks was roughly 15% on tirzepatide 5mg, 20% on 10mg and 21% on 15mg. Some people reach their goals on a lower or mid-range dose, which may cost less if their provider charges by strength. The decision about dose is clinical and depends on response and side effects. See the Mounjaro dosing schedule and Wegovy dosing schedule.

3. Provider fees and inclusions

Consultation fees, review fees, needles, sharps bins and delivery can add up over many months. Our guide to the hidden costs of private treatment lists what to check.

4. Price changes

List prices can change. The September 2025 Mounjaro increase is an example of how a manufacturer's decision can raise private costs significantly mid-treatment. Prices could also fall in future, but this is uncertain.

5. Breaks in treatment

Pauses for illness, surgery, pregnancy planning or supply problems can reduce spending in the short term, but restarting after a long gap may mean going back to a lower dose and repeating part of the titration.

6. Switching medicines or providers

Switching can change costs in either direction and may involve new consultation fees. See switching providers mid-treatment.

Planning a budget without prices

Because prices vary by provider and change over time, we cannot give figures here. But you can build your own estimate using this framework:

Doing this for one year and for three years can be a useful reality check. Our prices page shows what regulated providers include, which helps with steps 1 to 3.

Possible offsets: does treatment save money elsewhere?

Some people find their spending changes in other ways during treatment. For example:

• Food spending may fall because appetite is reduced, though healthier food choices can cost more.
• Alcohol spending may fall, as many people report drinking less.
• Prescriptions for other conditions may change if conditions such as type 2 diabetes or high blood pressure improve and a doctor reduces other medicines.

These effects vary widely and should not be relied on to justify or offset the cost of treatment. Never reduce or stop other prescribed medicines without your doctor's advice.

Health benefits and their value

Beyond weight, GLP-1 medicines have shown other health benefits in trials:

• SELECT found semaglutide 2.4mg reduced major cardiovascular events by about 20% in adults with overweight or obesity and established cardiovascular disease.
• Tirzepatide has shown improvements in obstructive sleep apnoea and substantially reduced progression to type 2 diabetes in people with prediabetes during extended follow-up of SURMOUNT-1.

These benefits are hard to put a personal price on, and they depend on continuing treatment. They are part of why NICE considered these medicines cost-effective for certain NHS patients. See Wegovy and the SELECT trial and tirzepatide and sleep apnoea.

How NICE assessed long-term value

NICE assesses whether a medicine provides good value for the NHS by comparing its costs with the health benefits it provides over time, usually measured in quality-adjusted life years. Its appraisals took account of the evidence on weight regain after stopping and, for the NHS, confidential prices agreed with manufacturers.

The two-year limit for Wegovy reflects the evidence available at the time of appraisal, which covered about two years of treatment (for example, STEP 5). It has raised questions about what happens when NHS treatment ends, since evidence suggests weight may be regained. Some people choose to continue privately. See Wegovy on the NHS and Mounjaro on the NHS.

Individual value is different. A person paying privately weighs the cost against their own health goals, finances and priorities, which no appraisal can do for them.

Thinking about value for you personally

Cost is easier to weigh when you are clear about what you hope treatment will achieve. People start GLP-1 medicines for different reasons, and the value they place on the outcome differs too.

Clarify your goals

Goals might include reducing the risk of type 2 diabetes or heart disease, improving sleep apnoea, joint pain or mobility, becoming eligible for another treatment such as joint replacement surgery, or simply feeling healthier day to day. Some goals depend on continued weight loss; others may be met with a moderate, sustained reduction. Discuss your goals with your prescriber, because they can influence decisions about dose and duration.

Consider what "success" looks like

Clinical guidance often uses a 5% loss of initial weight as a threshold for a meaningful response, and both NICE TA875 and TA1026 include a review at six months based on it. Many people lose much more than this, but even 5% to 10% weight loss can improve blood pressure, blood sugar and other markers. If your response is limited after several months on a well-tolerated dose, it may be worth reviewing with your prescriber whether to continue, switch or stop, rather than continuing to pay for treatment that is not helping. See GLP-1 non-responders and realistic weight loss expectations.

Weigh the alternatives

For some people, the long-term cost of medication may be weighed against other options, such as NHS lifestyle programmes, or, for those with a higher BMI and certain conditions, bariatric surgery, which involves a one-off procedure followed by lifelong follow-up. Our guide to GLP-1 medication vs bariatric surgery compares the two.

Be honest about affordability

It is better to plan a treatment you can sustain, or a well-supported stop, than to start a plan you cannot keep up and then stop abruptly. If finances change, talk to your prescriber rather than skipping doses or turning to unregulated sources, which can be dangerous.

Strategies people discuss with their prescriber

There is no single right approach. Options people commonly discuss include:

Continuing at a maintenance dose

Staying on the dose that achieved the result, with regular reviews. This offers the greatest likelihood of maintaining weight loss based on current evidence, but has the highest ongoing cost.

Holding at a lower dose

Some people stay on a lower dose that controls appetite adequately, rather than continuing to increase. This is only appropriate if clinically suitable, and your prescriber should monitor your weight and health.

Planned stopping with support

Some people choose to stop after reaching a goal, with a strong focus on diet, protein, strength training, sleep and regular weight monitoring, and a plan for what to do if weight starts to return. Our Mounjaro maintenance guide and Wegovy maintenance and stopping guides look at this in more detail.

Exploring NHS eligibility

NHS access to Mounjaro is being phased in, with criteria widening in later cohorts. Even if you do not qualify now, it is worth asking your GP periodically. See private vs NHS weight loss treatment.

Considering newer options

At the time of writing, the MHRA has authorised the Wegovy tablet (oral semaglutide) and Foundayo (orforglipron) for weight management. Whether these change long-term costs depends on pricing, availability and how well they work for you. They have not yet been through NICE appraisal for routine NHS use at the time of writing. See oral vs injectable GLP-1s.

Will costs come down?

It is natural to wonder whether costs will fall over time. Several factors could affect this:

• Competition. More medicines, including oral GLP-1s and future treatments, may increase competition. See the GLP-1 pipeline.
• Patent expiry. When patents on a medicine expire, cheaper generic versions can become available. Semaglutide patents are expiring in some countries from 2026, but timing varies by country and the UK position is likely to be later. Check current information rather than relying on predictions.
• NHS roll-out. Wider NHS access over time could mean more people are treated at no more than a prescription charge.
• Manufacturer pricing decisions. As 2025 showed, prices can also go up.

Because all of these are uncertain, it is safest to plan using current costs while recognising that they may change.

Long-term safety as well as cost

Cost is not the only long-term consideration. The longest trial data for these medicines in people without diabetes cover a few years, with SELECT following participants for an average of more than three years. Semaglutide and related medicines have been used in type 2 diabetes for longer. Long-term monitoring for rare side effects continues, and your prescriber should review whether continuing is still right for you at regular intervals. See long-term GLP-1 use.

You can compare regulated private providers on our providers page, or read more about all the options in our overview of weight loss injections.

Questions to ask before you start

• How long do people typically stay on this medicine, and what happens if I stop?
• What dose am I likely to need, and how will we decide whether to increase?
• If cost becomes a problem, what are the safe options?
• How will you support me if I decide to stop?
• How will you let me know about price changes?
• Am I likely to qualify for NHS treatment now or in future?

When to speak to a professional

Talk to your GP, pharmacist or prescriber before starting a GLP-1 medicine, and before any change to your dose or plan to stop. Do not stop other prescribed medicines because your health has improved without speaking to your doctor first. If you have diabetes, your diabetes medicines may need adjusting as your weight changes.

Seek urgent medical help (NHS 111, or 999 in an emergency) if you experience:

• severe, persistent abdominal pain, possibly spreading to your back, with or without vomiting (possible pancreatitis)
• pain in the upper right abdomen, fever, or yellowing of the skin or eyes (possible gallbladder problems)
• persistent vomiting or diarrhoea with signs of dehydration
• swelling of the face, lips or throat, or difficulty breathing
• symptoms of low blood sugar if you take diabetes medicines
• new or worsening low mood or thoughts of self-harm

Report suspected side effects to the MHRA through the Yellow Card scheme.